Niemoeller, Elisabeth

Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin

Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 288

Teplizumab and β-cell function in newly diagnosed type 1 diabetes

Ramos, E. L., Dayan, C. M., Chatenoud, L., Sumnik, Z., Simmons, K. M., Szypowska, A., Gitelman, S. E., Knecht, L. A., Niemoeller, E., Tian, W., et al. (2023) · New England Journal of Medicine

Diabetes and associated disordersDiabetes Management and Research

Cited by 273

Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: the LixiLan-L randomized trial

Aroda, V. R., Rosenstock, J., Wysham, C., Unger, J., Bellido, D., González-Gálvez, G., Takami, A., Guo, H., Niemoeller, E., Souhami, E., et al. (2016) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 260

Efficacy and safety of lixisenatide once daily vs. placebo in people with type 2 diabetes insufficiently controlled on metformin (GetGoal-F1)

Bolli, G. B., Munteanu, M., Dotsenko, S., Niemoeller, E., Boka, G., Wu, Y., & Hanefeld, M. (2014) · Diabetic Medicine

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 144

Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial

Lam, C. S. P., Ramasundarahettige, C., Branch, K. R. H., Sattar, N., Rosenstock, J., Pratley, R., Del Prato, S., Lopes, R. D., Niemoeller, E., Khurmi, N. S., et al. (2022) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 132

Switching to iGlarLixi versus continuing daily or weekly GLP-1 RA in type 2 diabetes inadequately controlled by GLP-1 RA and oral antihyperglycemic therapy: the LixiLan-G randomized clinical trial

Blonde, L., Rosenstock, J., Del Prato, S., Henry, R., Shehadeh, N., Frias, J., Niemoeller, E., Souhami, E., Ji, C., & Aroda, V. R. (2019) · Diabetes Care

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 85

Efficacy and safety of insulin glargine/lixisenatide fixed-ratio combination (iGlarLixi) in Japanese patients with type 2 diabetes mellitus inadequately controlled on basal insulin and oral antidiabetic drugs: The LixiLan JP-l randomized clinical trial

Kaneto, H., Takami, A., Spranger, R., Amano, A., Watanabe, D., & Niemoeller, E. (2020) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 36

Lower risk of severe hypoglycaemia with insulin glargine 300 U/ mL versus glargine 100 U/ mL in participants with type 1 diabetes: A meta‐analysis of 6‐month phase 3 clinical trials

Danne, T., Matsuhisa, M., Sussebach, C., Goyeau, H., Lauand, F., Niemoeller, E., & Bolli, G. B. (2020) · Diabetes, Obesity and Metabolism

Diabetes Management and ResearchDiabetes Treatment and Management

Cited by 25

Efficacy and safety of lixisenatide in Japanese patients with type 2 diabetes mellitus inadequately controlled by sulfonylurea with or without metformin: Subanalysis of GetGoal‐S

Onishi, Y., Niemoeller, E., Ikeda, Y., Takagi, H., Yabe, D., & Seino, Y. (2015) · Journal of Diabetes Investigation

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 13